Skip to content
Assyro AI
Orange Book drug · Brand (NDA)

Abraxane

Paclitaxel

RLDNDA 021660 Bristol-myers
Approved
Jan 07, 2005
Strengths
1
Listed patents
14

What does the FDA Orange Book show for Abraxane?

Abraxane contains Paclitaxel and is the new drug FDA Orange Book record for NDA 021660. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application
NDA 021660

New drug application identity from the Orange Book snapshot.

Application holder
Bristol-myers Squibb Co

The listed applicant holds the FDA application; this field does not establish the product manufacturer.

Product presentations
1

Each FDA product number remains tied to its own strength, dosage form, route, and status.

Marketing categories
Prescription

Orange Book marketing categories do not establish real-time inventory or commercial availability.

Reference roles
RLD / RS

RLD and RS designations are presentation-specific, not inferred from the trade name.

TE codes
AB

Therapeutic-equivalence codes apply only within the matching Orange Book product heading.

Listed patents
14

A zero means none appear in this snapshot, not that no patent rights exist.

Exclusivity records
0

FDA exclusivity and listed patent protection are distinct regulatory concepts.

Sourced from the official FDA Orange Book data file · snapshot refreshed

FDA product-presentation matrix

Every product number in this exact application
Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
ProductStrengthDosage form / routeMarketing statusTE codeReference role
001100MG/VIALPOWDERINTRAVENOUSPrescriptionAB
RLDRS

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Bristol-myers Squibb Co

The Orange Book identifies this organization as the applicant responsible for NDA 021660.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not
FDA marketing status

1 presentation listed as prescription

RX and OTC are Orange Book marketing categories, not real-time inventory signals. Confirm current commercial availability with labeling, the application holder, or an authoritative drug listing.

Therapeutic equivalence

TE code AB across rated presentations

An AB code is an A-rating: FDA considers the product therapeutically equivalent to pharmaceutical equivalents in the same Orange Book heading and equivalence group.

Patent & exclusivity record

11 listed patent expirations and 0 exclusivity dates remain on or after Jul 26, 2026

The latest future date recorded across those files is Jul 12, 2034. Patent and FDA exclusivity operate independently, can overlap, and do not by themselves predict a generic launch date.

Same-ingredient landscape

20 other ANDAs and 3 other NDAs found

13 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

NDA 021660 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Why are clinical sections unavailable?

Exact application-label matching status
Exact source match queuedQueue NDA-021660

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

NDA 021660
TE ABRLDRS
Strength
100MG/VIAL
Dosage form
POWDER
Route
INTRAVENOUS
Marketing status
Prescription

Key dates

Approval, patents, exclusivity

  1. Approval

    FDA approval date of this drug product.

    21 yr 10 mo ago

  2. Patent 7758891 expires

    Listed method-of-use patent (U-1434) expiration.

    5 mo ago

  3. Patent 8268348 expires

    Listed method-of-use patent (U-1290) expiration.

    5 mo ago

  4. Patent 9101543 expires

    Listed method-of-use patent (U-1434) expiration.

    5 mo ago

  5. Today

  6. Patent 8034375 expires

    Listed method-of-use patent (U-1290) expiration.

    in 18 d

  7. Patent 7758891*PED expires

    Listed listed patent expiration.

    in 26 d

  8. Patent 8268348*PED expires

    Listed listed patent expiration.

    in 26 d

  9. Patent 9101543*PED expires

    Listed listed patent expiration.

    in 26 d

  10. Patent 8034375*PED expires

    Listed listed patent expiration.

    in 7 mo

  11. Patent 9393318 expires

    Listed method-of-use patent (U-1290) expiration.

    in 5 yr 8 mo

  12. Patent 9597409 expires

    Listed method-of-use patent (U-1290) expiration.

    in 5 yr 8 mo

  13. Patent 9393318*PED expires

    Listed listed patent expiration.

    in 6 yr 2 mo

  14. Patent 9597409*PED expires

    Listed listed patent expiration.

    in 6 yr 2 mo

  15. Patent 9511046 expires

    Listed method-of-use patent (U-1434) expiration.

    in 7 yr 7 mo

  16. Patent 9511046*PED expires

    Listed listed patent expiration.

    in 8 yr 1 mo

Patent & exclusivity timeline

Protection horizon
2026202720282029203020312032203320342035TodayPatent 7758891: 2026-02-21Patent 7758891Patent 8268348: 2026-02-21Patent 8268348Patent 9101543: 2026-02-21Patent 9101543Patent 8034375: 2026-08-13Patent 8034375Patent 7758891*PED: 2026-08-21Patent 7758891*PEDPatent 8268348*PED: 2026-08-21Patent 8268348*PEDPatent 9101543*PED: 2026-08-21Patent 9101543*PEDPatent 8034375*PED: 2027-02-13Patent 8034375*PEDPatent 9393318: 2032-03-04Patent 9393318Patent 9597409: 2032-03-04Patent 9597409Patent 9393318*PED: 2032-09-04Patent 9393318*PEDPatent 9597409*PED: 2032-09-04Patent 9597409*PEDPatent 9511046: 2034-01-12Patent 9511046Patent 9511046*PED: 2034-07-12Patent 9511046*PED
Patent expiryExclusivity endToday

Pharmaceutical detail

FDA product record

Active ingredient

PACLITAXEL

Strength

100MG/VIAL

Dosage form

POWDER

Route

INTRAVENOUS

TE code

AB

Application

NDA 021660

Product number

001

Marketing status

Prescription

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
77588915 mo ago
U-1434
82683485 mo ago
U-1290
91015435 mo ago
U-1434
8034375in 18 d
U-1290
7758891*PEDin 26 d
8268348*PEDin 26 d
9101543*PEDin 26 d
8034375*PEDin 7 mo
9393318in 5 yr 8 mo
U-1290
9597409in 5 yr 8 mo
U-1290
9393318*PEDin 6 yr 2 mo
9597409*PEDin 6 yr 2 mo
9511046in 7 yr 7 mo
U-1434
9511046*PEDin 8 yr 1 mo

Active-ingredient family

Brand + generics

This is a reference-listed drug (RLD), the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

View full Paclitaxel family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

  • The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
  • RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
  • Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
  • Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
  • The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.

Abraxane: frequently asked questions

Approval, therapeutic equivalence, patents, and exclusivity for this drug, from the FDA Orange Book.

Built directly from the FDA Orange Book product, patent, and exclusivity files refreshed Jul 02, 2026, 06:34 PM. Every strength of NDA 021660 is shown on this page. Interpret patents, exclusivity, availability, and therapeutic equivalence using the limitations above.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo